AMG 305 represents an innovative dual-targeting BiTE (bispecific T-cell engager) molecule, specifically engineered with a half-life extended (HLE) format. This molecule uniquely targets both P-cadherin (CDH3) and mesothelin (MSLN) on tumor cells, in addition to CD3 on T-cells. The design of AMG 305 aims to enhance the therapeutic index in solid tumors by selectively engaging T-cells to tumor cells that co-express CDH3 and MSLN, while minimizing interaction with normal cells that express only one of these antigens. This selective mechanism of action positions AMG 305 as a promising candidate for targeted cancer therapy, especially in settings where both CDH3 and MSLN are overexpressed.
AMG 305 represents an innovative dual-targeting BiTE (bispecific T-cell engager) molecule, specifically engineered with a half-life extended (HLE) format. This molecule uniquely targets both P-cadherin (CDH3) and mesothelin (MSLN) on tumor cells, in addition to CD3 on T-cells. The design of AMG 305 aims to enhance the therapeutic index in solid tumors by selectively engaging T-cells to tumor cells that co-express CDH3 and MSLN, while minimizing interaction with normal cells that express only one of these antigens. This selective mechanism of action positions AMG 305 as a promising candidate for targeted cancer therapy, especially in settings where both CDH3 and MSLN are overexpressed.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
